title: HbA1C - overall glycemia marker and hemolytic anemia indicator.
abstract: Glycated hemoglobin A1C reflects a mean glycemia over the preceding 3 months (erythrocyte life span). In diabetes management, target value is set below 6.5%, to reduce the risk of chronic complications. However, there are different conditions that lead to a shortened lifespan of erythrocytes, resulting in falsely low HbA1C value. Case presented involves a 72-year-old patient with history of diabetes and possible iatrogenic-induced autoimmune hemolytic anemia. Thus, HbA1C may be a screening test for hemolysis in non-diabetic patients with hemolytic anemia, but in diabetic population with hemolytic disease it is considered to be a very poor marker for both, overall glycemia and haemolysis.
authors.affiliation: Department of Internal Medicine, General Hospital Dr. Josip Benčević, Slavonski Brod, Croatia. marica@jandric.com
authors.forename: Marica
authors.initials: M
authors.lastname: Jandrić Balen
authors.forename: Vesna
authors.initials: V
authors.lastname: Lukenda
authors.forename: Ivan
authors.initials: I
authors.lastname: Jandrić
authors.forename: Antonija
authors.initials: A
authors.lastname: Raguž
authors.forename: Sidbela
authors.initials: S
authors.lastname: Zukanović
authors.forename: Blaženka
authors.initials: B
authors.lastname: Miškić
mesh_terms: D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis* / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin